Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-expected first-quarter 2026 results.

GAITHERSBURG, Md., Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two ...

Novavax received emergency use authorization for an updated vaccine. The biotech is benefiting from a partnership with Sanofi. However, its prospects remain unpredictable. Though we are no longer in a ...

Novavax recently made a move that improved its financial position and prospects. The biotech has two pivotal clinical trials in the works. Those headwinds included the difficulties it faced in ...

Vaccine Maker Also Reported Q1 Earnings That Missed Estimates Friday Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the ...

By Siddhi Mahatole and Michael Erman May 6 (Reuters) - Novavax on Wednesday beat Wall Street estimates for first-quarter ...

We expect Novavax NVAX to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell. The company’s earnings beat estimates by 32% in the last reported quarter.

A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica was a writer on the Wellness team, with a focus on health ...

Add Yahoo as a preferred source to see more of our stories on Google. Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other ...

Five years ago, Novavax (NASDAQ: NVAX) was a little-known clinical-stage biotech whose leading pipeline candidate was an influenza vaccine. Then came the pandemic. The company quickly grew in ...